<DOC>
	<DOCNO>NCT00153868</DOCNO>
	<brief_summary>This web-based pilot study evaluate association treatment anemia darbepoetin alfa ( aranesp ) clinical benefit symptom palliation , improve functional status quality life patient cancer . The feasibility web-based assessment data capture evaluate .</brief_summary>
	<brief_title>A Web-based Study Quality Life Benefits Associated Aranesp Anemic Patients With Cancer</brief_title>
	<detailed_description>Anemia associate lung cancer chemotherapy important factor effect patient symptom , functional status , overall quality life ( Groopman Itri 1999 ; Langer , Choy et al . 2002 ) . Darbepoetin alfa ( Aranesp® ) demonstrate significant effect upon ameliorate chemotherapy-induced anemia lung cancer ( Vansteenkiste , Pirker et al . 2002 ; Vansteenkiste , Poulsen et al . 2002 ) . This trial design evaluate association treatment anemia darbepoetin alfa direct electronic capture clinical benefit cancer-related symptom , functional status overall quality life . This trial use secure web-based design capture patient-associated symptom , functional status quality life . This novel secure web-based system select improve efficiency quality clinical data capture . If hypothesis correct , treatment darbepoetin alfa associate improved palliation cancer-related symptom , improve functional status , result overall benefit patient 's health-related quality life . The development web-based system directly capture patient-related symptom , functional status quality life permit u future conduct national international trial address effect darbepoetin alfa factor . If hypothesis incorrect , may parameter affect correction anemia darbepoetin alfa measure sensitive enough detect difference . A notable finding would clearly define improvement symptom palliation , functional status , quality life associate darbepoetin alfa therapy .</detailed_description>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Confirmation nonmyeloid cancer ( myeloproliferative disorder exclude ) . Hemoglobin concentration ≤ 11.0 g/dL . Age ≥ 18 year . Karnofsky performance status ≥ 60 % . Anemia predominantly due cancer chemotherapy . Serum creatinine concentration ≤ 2.0 mg/dL . Total serum bilirubin ≤ 1.5 time upper limit normal . Nutritional status adequate provide vitamin B12 folate within normal limit . Capacity complete webbased functional status , symptom quality life assessment . Ability give inform consent . Untreated symptomatic primary metastatic cancer involve central nervous system . History clinically significant iron deficiency . Greater two red blood cell transfusion within 2 week registration red blood cell transfusion within 7 day registration . Received epoetin alfa darbepoetin alfa therapy within 3 week prior randomization . History seizure disorder . Unstable angina , congestive heart failure ( New York Heart Association &gt; class II know ejection fraction &lt; 40 % ) uncontrolled cardiac arrhythmia . Uncontrolled hypertension define diastolic blood pressure &gt; 100 mmHg . Clinical evidence active infection inflammatory disease rheumatoid arthritis . Subjects active rheumatoid arthritis exclude . Known positive test human immunodeficiency virus infection . Known primary hematological disorder could cause anemia sickle cell anemia . Pregnant breastfeeding . Not use adequate contraception childbearing potential . Known hypersensitivity recombinant mammalianderived product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Cancer</keyword>
	<keyword>Quality life</keyword>
	<keyword>Web-based</keyword>
	<keyword>Aranesp</keyword>
	<keyword>Darbepoetin alfa</keyword>
</DOC>